SEARCH

SEARCH BY CITATION

References

  • 1
    Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-1578.
  • 2
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  • 3
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
  • 4
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 5
    Bacon B, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 6
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 7
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
  • 8
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
  • 9
    Sherman KE. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
  • 10
    Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 69-71.
  • 11
    Foy E, Li K, Wang C, Sumpter R, Jr., Ikeda M, Lemon SM, Gale M, Jr. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148.
  • 12
    Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102: 2992-2997.
  • 13
    Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114-1122.
  • 14
    Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van't Klooster G, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138: 913-921.
  • 15
    Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, et al. Rapid viral response of once daily TMC435 plus pegylated interferon / ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011; 16: 1021-1033.
  • 16
    Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, et al. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study. J Hepatol 2011; 54: 1130-1136.
  • 17
    Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 2010; 54: 305-311.
  • 18
    Lawitz EJ, Sulkowski MS, Jacobson IM, Faruqui S, Kraft WK, Maliakkal B, et al. Safety, tolerability, and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection [abstract]. HEPATOLOGY 2011; 48( Suppl 4): 403A.
  • 19
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 20
    Fried MW, Buti M, Dore GJ, Ferenci P, Jacobson IM, Marcellin P, et al. Efficacy and safety of TMC435 in combination with peginterferon alfa 2a and ribavirin in treatment-naïve genotype-1 HCV patients: 24-week interim results from the PILLAR study [abstract]. HEPATOLOGY 2010; 52( Suppl 4): LB-5.
  • 21
    Flisiak R, Pawlotsky JM, Crabbé R, Kryczka W, Haüssinger D, Mazella G, et al. Once daily alisporivir (DEB025) plus pegifnalfa2A/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients [abstract]. J Hepatol 2011; 54( Suppl 1): S2.
  • 22
    Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192-206.
  • 23
    Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54: 1878- 1887.
  • 24
    Courcambeck J, Bouzidi M, Perbost R, Jouirou B, Amrani N, Cacoub P, et al. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A, and D168V mutations. Antivir Ther 2006; 11: 847-855.
  • 25
    Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280: 36784-36791.
  • 26
    McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53: 2129-2132.
  • 27
    Lawitz E, Sulkowski M, Jacobson I, Faruqui S, Kraft W, Maliakkal B, et al. Safety, tolerability, and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases, October 31-November 4, 2008, San Francisco, CA.